354 related articles for article (PubMed ID: 16540668)
1. Levels of HdmX expression dictate the sensitivity of normal and transformed cells to Nutlin-3.
Patton JT; Mayo LD; Singhi AD; Gudkov AV; Stark GR; Jackson MW
Cancer Res; 2006 Mar; 66(6):3169-76. PubMed ID: 16540668
[TBL] [Abstract][Full Text] [Related]
2. HDM2 antagonist Nutlin-3 disrupts p73-HDM2 binding and enhances p73 function.
Lau LM; Nugent JK; Zhao X; Irwin MS
Oncogene; 2008 Feb; 27(7):997-1003. PubMed ID: 17700533
[TBL] [Abstract][Full Text] [Related]
3. Hdmx modulates the outcome of p53 activation in human tumor cells.
Wade M; Wong ET; Tang M; Stommel JM; Wahl GM
J Biol Chem; 2006 Nov; 281(44):33036-44. PubMed ID: 16905769
[TBL] [Abstract][Full Text] [Related]
4. p53 promotes its own polyubiquitination by enhancing the HDM2 and HDMX interaction.
Medina-Medina I; Martínez-Sánchez M; Hernández-Monge J; Fahraeus R; Muller P; Olivares-Illana V
Protein Sci; 2018 May; 27(5):976-986. PubMed ID: 29524278
[TBL] [Abstract][Full Text] [Related]
5. Identification of an aberrantly spliced form of HDMX in human tumors: a new mechanism for HDM2 stabilization.
Giglio S; Mancini F; Gentiletti F; Sparaco G; Felicioni L; Barassi F; Martella C; Prodosmo A; Iacovelli S; Buttitta F; Farsetti A; Soddu S; Marchetti A; Sacchi A; Pontecorvi A; Moretti F
Cancer Res; 2005 Nov; 65(21):9687-94. PubMed ID: 16266988
[TBL] [Abstract][Full Text] [Related]
6. BH3 activation blocks Hdmx suppression of apoptosis and cooperates with Nutlin to induce cell death.
Wade M; Rodewald LW; Espinosa JM; Wahl GM
Cell Cycle; 2008 Jul; 7(13):1973-82. PubMed ID: 18604177
[TBL] [Abstract][Full Text] [Related]
7. Alterations in gene expression and sensitivity to genotoxic stress following HdmX or Hdm2 knockdown in human tumor cells harboring wild-type p53.
Heminger K; Markey M; Mpagi M; Berberich SJ
Aging (Albany NY); 2009 Jan; 1(1):89-108. PubMed ID: 19946469
[TBL] [Abstract][Full Text] [Related]
8. Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1.
Ambrosini G; Sambol EB; Carvajal D; Vassilev LT; Singer S; Schwartz GK
Oncogene; 2007 May; 26(24):3473-81. PubMed ID: 17146434
[TBL] [Abstract][Full Text] [Related]
9. HdmX stimulates Hdm2-mediated ubiquitination and degradation of p53.
Linares LK; Hengstermann A; Ciechanover A; Müller S; Scheffner M
Proc Natl Acad Sci U S A; 2003 Oct; 100(21):12009-14. PubMed ID: 14507994
[TBL] [Abstract][Full Text] [Related]
10. HDM2 and HDMX Proteins in Human Cancer.
Hároníková L; Vojtěšek B
Klin Onkol; 2018; 31(Suppl 2):63-70. PubMed ID: 31023026
[TBL] [Abstract][Full Text] [Related]
11. HDMX-L is expressed from a functional p53-responsive promoter in the first intron of the HDMX gene and participates in an autoregulatory feedback loop to control p53 activity.
Phillips A; Teunisse A; Lam S; Lodder K; Darley M; Emaduddin M; Wolf A; Richter J; de Lange J; Verlaan-de Vries M; Lenos K; Böhnke A; Bartel F; Blaydes JP; Jochemsen AG
J Biol Chem; 2010 Sep; 285(38):29111-27. PubMed ID: 20659896
[TBL] [Abstract][Full Text] [Related]
12. E2F-1 transcriptional activity is a critical determinant of Mdm2 antagonist-induced apoptosis in human tumor cell lines.
Kitagawa M; Aonuma M; Lee SH; Fukutake S; McCormick F
Oncogene; 2008 Sep; 27(40):5303-14. PubMed ID: 18521084
[TBL] [Abstract][Full Text] [Related]
13. HdmX overexpression inhibits oncogene induced cellular senescence.
Miller KR; Kelley K; Tuttle R; Berberich SJ
Cell Cycle; 2010 Aug; 9(16):3376-82. PubMed ID: 20724842
[TBL] [Abstract][Full Text] [Related]
14. Elevated MDM2 boosts the apoptotic activity of p53-MDM2 binding inhibitors by facilitating MDMX degradation.
Xia M; Knezevic D; Tovar C; Huang B; Heimbrook DC; Vassilev LT
Cell Cycle; 2008 Jun; 7(11):1604-12. PubMed ID: 18520179
[TBL] [Abstract][Full Text] [Related]
15. Histone deacetylase inhibitors enhance the anticancer activity of nutlin-3 and induce p53 hyperacetylation and downregulation of MDM2 and MDM4 gene expression.
Palani CD; Beck JF; Sonnemann J
Invest New Drugs; 2012 Feb; 30(1):25-36. PubMed ID: 20680659
[TBL] [Abstract][Full Text] [Related]
16. Restoration of p53 pathway by nutlin-3 induces cell cycle arrest and apoptosis in human rhabdomyosarcoma cells.
Miyachi M; Kakazu N; Yagyu S; Katsumi Y; Tsubai-Shimizu S; Kikuchi K; Tsuchiya K; Iehara T; Hosoi H
Clin Cancer Res; 2009 Jun; 15(12):4077-84. PubMed ID: 19509161
[TBL] [Abstract][Full Text] [Related]
17. Identification of a Small Molecule That Overcomes HdmX-Mediated Suppression of p53.
Karan G; Wang H; Chakrabarti A; Karan S; Liu Z; Xia Z; Gundluru M; Moreton S; Saunthararajah Y; Jackson MW; Agarwal MK; Wald DN
Mol Cancer Ther; 2016 Apr; 15(4):574-582. PubMed ID: 26883273
[TBL] [Abstract][Full Text] [Related]
18. Nutlin-3, an Hdm2 antagonist, inhibits tumor adaptation to hypoxia by stimulating the FIH-mediated inactivation of HIF-1alpha.
Lee YM; Lim JH; Chun YS; Moon HE; Lee MK; Huang LE; Park JW
Carcinogenesis; 2009 Oct; 30(10):1768-75. PubMed ID: 19696166
[TBL] [Abstract][Full Text] [Related]
19. Nutlin-3, a small-molecule MDM2 inhibitor, sensitizes Caki cells to TRAIL-induced apoptosis through p53-mediated PUMA upregulation and ROS-mediated DR5 upregulation.
Park EJ; Choi KS; Yoo YH; Kwon TK
Anticancer Drugs; 2013 Mar; 24(3):260-9. PubMed ID: 23187459
[TBL] [Abstract][Full Text] [Related]
20. The MDM2 antagonist nutlin-3 sensitizes p53-null neuroblastoma cells to doxorubicin via E2F1 and TAp73.
Peirce SK; Findley HW
Int J Oncol; 2009 May; 34(5):1395-402. PubMed ID: 19360352
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]